Malik Azhar1,2, Faisal Aziz3,4, Salama Almuhairi5, Mohammad Alfelasi5, Ali Elhouni1, Rizwan Syed6, Humaid O Al-Shamsi7,8,9, Khaled M Aldahmani1,2. 1. Endocrine Division, Tawam Hospital, Al Ain, United Arab Emirates. 2. Departments of Medicine, College of Medicine and Health Science, UAE University, United Arab Emirates. 3. Division of Endocrinology and Diabetes, Medical University of Graz, Graz, Austria. 4. Center for Biomarker Research in Medicine - CBMed, Graz, Austria. 5. ENT Division, Tawam Hospital, Al Ain, United Arab Emirates. 6. Radiology Department, Tawam Hospital, Al Ain, United Arab Emirates. 7. Emirates Oncology Society, Dubai, United Arab Emirates. 8. College of Medicine, University of Sharjah, Sharjah, United Arab Emirates. 9. Burjeel Cancer Institute, Mohamed Bin Zayed City, Abu Dhabi, United Arab Emirates.
Abstract
OBJECTIVES: To assess the trend of clinicopathological features and treatment modalities in patients with thyroid cancer (TC) in the largest oncology center in the United Arab Emirates (UAE). METHODS: A retrospective analysis of patients with TC presenting to a tertiary care hospital in Al Ain, UAE between September 2008 and December 2018 identified using ICD 9 & 10 codes was performed. Data on demographics, histopathology, surgical extent, and use of Radioiodine (RAI) were extracted. Exact logistic and ordinal logistic regressions were performed to analyze the annual trend in features and management of TC, and logistic regression analysis was performed to identify predictors of total thyroidectomy and RAI use. RESULTS: A total of 762 patients were included in the analysis (mean age: 39.6 ± 12.6 years, 45 (60%) women). The majority (92.2%) were diagnosed with papillary thyroid cancer (PTC) and 83.9% had tumor size of <4 cm. All patients underwent surgery (93.8% total thyroidectomy, 6.2% lobectomy) and 77.4% received RAI therapy overall with a significant (p < 0.001) decline from 100% in 2008 to 60% in 2018. In multivariate analysis, nationality, and lymph node (LN) involvement were significant predictors of total thyroidectomy, while nationality, LNs, year of diagnosis, and tumor size significantly predicted RAI use. CONCLUSION: Most patients in our cohort were diagnosed with localized PTC with no significant change in the extent of surgical approach but a substantial decline in RAI therapy administration over time. Nationality and LN involvement were significant predictors of surgical extent and RAI use.
OBJECTIVES: To assess the trend of clinicopathological features and treatment modalities in patients with thyroid cancer (TC) in the largest oncology center in the United Arab Emirates (UAE). METHODS: A retrospective analysis of patients with TC presenting to a tertiary care hospital in Al Ain, UAE between September 2008 and December 2018 identified using ICD 9 & 10 codes was performed. Data on demographics, histopathology, surgical extent, and use of Radioiodine (RAI) were extracted. Exact logistic and ordinal logistic regressions were performed to analyze the annual trend in features and management of TC, and logistic regression analysis was performed to identify predictors of total thyroidectomy and RAI use. RESULTS: A total of 762 patients were included in the analysis (mean age: 39.6 ± 12.6 years, 45 (60%) women). The majority (92.2%) were diagnosed with papillary thyroid cancer (PTC) and 83.9% had tumor size of <4 cm. All patients underwent surgery (93.8% total thyroidectomy, 6.2% lobectomy) and 77.4% received RAI therapy overall with a significant (p < 0.001) decline from 100% in 2008 to 60% in 2018. In multivariate analysis, nationality, and lymph node (LN) involvement were significant predictors of total thyroidectomy, while nationality, LNs, year of diagnosis, and tumor size significantly predicted RAI use. CONCLUSION: Most patients in our cohort were diagnosed with localized PTC with no significant change in the extent of surgical approach but a substantial decline in RAI therapy administration over time. Nationality and LN involvement were significant predictors of surgical extent and RAI use.
Authors: Wouter P Kluijfhout; Jesse D Pasternak; James Lim; Julie S Kwon; Menno R Vriens; Orlo H Clark; Wen T Shen; Jessica E Gosnell; Insoo Suh; Quan-Yang Duh Journal: Thyroid Date: 2016-05-20 Impact factor: 6.568
Authors: Megan R Haymart; Mousumi Banerjee; Andrew K Stewart; Ronald J Koenig; John D Birkmeyer; Jennifer J Griggs Journal: JAMA Date: 2011-08-17 Impact factor: 56.272
Authors: Briseis A Kilfoy; Tongzhang Zheng; Theodore R Holford; Xuesong Han; Mary H Ward; Andreas Sjodin; Yaqun Zhang; Yana Bai; Cairong Zhu; Grace L Guo; Nathaniel Rothman; Yawei Zhang Journal: Cancer Causes Control Date: 2008-11-19 Impact factor: 2.506